I don't think any of the geron longs doubt that they have their IND act together. However, so far, during this administration, the FDA top brass have been compelled to delay approval of drugs that the biologics panels have said were good to go. It would be much easier to put up roadblocks infront of the clinical trials to prevent them from moving forward than to try and stop this after, say, some remarkable results get out into the mainstream press. All that has to happen is for the FDA to keep asking more and more questions of Geron, like they did with Stem on their Batten treatment application.
Perhaps I am being overly concerned here, but you yourself have been witness to the shenanigans pulled by the RR's and this pandering administration.
Market Data 
Markets 
AI
